Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-03-13 Cobb Stuart Chief Scientific Officer Sale 10b5-1 −3,991 $20.41 $81K 33,303
2026-03-13 Cobb Stuart Chief Scientific Officer Sale 10b5-1 −2,658 $21.34 $57K 30,645
2026-03-13 Cobb Stuart Chief Scientific Officer Sale 10b5-1 −148 $22.08 $3K 30,497
2026-02-20 Cobb Stuart Chief Scientific Officer Grant or award +16,500 37,294
2025-05-14 Cobb Stuart Chief Scientific Officer Sale 10b5-1 −6,797 $15.15 $103K 20,794
2025-03-26 Cobb Stuart Chief Scientific Officer Grant or award +7,200 27,591
2025-03-26 Cobb Stuart Chief Scientific Officer Grant or award · Employee Stock Option (Right to buy) +42,900 42,900
2024-03-13 Cobb Stuart Chief Scientific Officer Grant or award +20,391 20,391
2024-03-13 Cobb Stuart Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +34,450 34,450

Page 1 of 1 · 9 trades